Matthew Szot Sells 1,600 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CFO Matthew Szot sold 1,600 shares of the firm’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $13.99, for a total transaction of $22,384.00. Following the transaction, the chief financial officer owned 31,733 shares of the company’s stock, valued at approximately $443,944.67. The trade was a 4.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Cadrenal Therapeutics Stock Performance

Cadrenal Therapeutics stock opened at $12.96 on Monday. Cadrenal Therapeutics, Inc. has a 52-week low of $6.89 and a 52-week high of $22.90. The firm has a 50 day moving average price of $11.81 and a two-hundred day moving average price of $14.80. The firm has a market cap of $26.57 million, a price-to-earnings ratio of -1.46 and a beta of 0.94.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.27). As a group, equities research analysts predict that Cadrenal Therapeutics, Inc. will post -7.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cadrenal Therapeutics stock. Geode Capital Management LLC bought a new stake in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned 0.59% of Cadrenal Therapeutics as of its most recent SEC filing. 7.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $32.00 price objective on shares of Cadrenal Therapeutics in a research note on Friday, May 16th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $32.00.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.